This uptick was mainly attributable to inventory buildup ahead of the potential commercial launch of Viaskin Peanut in the United States, as well as clinical expenditures related to the COMFORT Toddlers study and headcount expansion.

Furthermore, SG&A expenses rose by 4.6 million USD year-over-year, reflecting increased staffing levels and market research initiatives in preparation for the U.S. commercialization of Viaskin Peanut, pending regulatory approval.

The biotech firm's operating income reached 5.6 million USD in 2025, up from 4.2 million USD the previous year, largely due to an increase in activities eligible for research tax credits.

DBV reported cash and cash equivalents of 194 million USD as of December 31, 2025. Supplemented by 94 million USD in additional gross proceeds received on January 16, 2026, the company's current cash runway is expected to fund operations through the second quarter of 2027.